ATE492276T1 - Sphingosinkinase und deren verwendungen - Google Patents

Sphingosinkinase und deren verwendungen

Info

Publication number
ATE492276T1
ATE492276T1 AT01929118T AT01929118T ATE492276T1 AT E492276 T1 ATE492276 T1 AT E492276T1 AT 01929118 T AT01929118 T AT 01929118T AT 01929118 T AT01929118 T AT 01929118T AT E492276 T1 ATE492276 T1 AT E492276T1
Authority
AT
Austria
Prior art keywords
cancers
growth
sphingosine kinase
present
cells
Prior art date
Application number
AT01929118T
Other languages
English (en)
Inventor
Mathew Vadas
Jennifer Gamble
Pu Xia
Lijun Wang
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Application granted granted Critical
Publication of ATE492276T1 publication Critical patent/ATE492276T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01929118T 2000-05-11 2001-05-11 Sphingosinkinase und deren verwendungen ATE492276T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ7447A AUPQ744700A0 (en) 2000-05-11 2000-05-11 A method of treatment and agents useful for same
PCT/AU2001/000539 WO2001085953A1 (en) 2000-05-11 2001-05-11 Sphingosine kinase and uses thereof

Publications (1)

Publication Number Publication Date
ATE492276T1 true ATE492276T1 (de) 2011-01-15

Family

ID=3821526

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01929118T ATE492276T1 (de) 2000-05-11 2001-05-11 Sphingosinkinase und deren verwendungen

Country Status (17)

Country Link
US (1) US20040014635A1 (de)
EP (1) EP1290182B1 (de)
JP (1) JP2003532423A (de)
CN (1) CN1436241A (de)
AT (1) ATE492276T1 (de)
AU (3) AUPQ744700A0 (de)
BR (1) BR0110759A (de)
CA (1) CA2408196A1 (de)
DE (1) DE60143697D1 (de)
HK (1) HK1054409A1 (de)
IL (1) IL152672A0 (de)
MX (1) MXPA02011112A (de)
NO (1) NO20025375L (de)
NZ (1) NZ543272A (de)
RU (1) RU2326690C2 (de)
WO (1) WO2001085953A1 (de)
ZA (1) ZA200209066B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
WO2002051439A2 (en) 2000-12-22 2002-07-04 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
AU2003216076A1 (en) * 2002-01-17 2003-09-02 Children's Hospital And Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
JP2005526809A (ja) * 2002-03-28 2005-09-08 メドベット サイエンス ピーティーワイ． リミティッド 細胞活性を調節する方法
CA2502257A1 (en) * 2002-10-14 2004-04-29 Jennifer Ruth Gamble A method of modulating endothelial cell activity by modulating the functional levels level of sphingosine kinase
EP1570081A4 (de) * 2002-11-19 2006-05-31 Amgen Inc An krebs beteiligte amplifizierte gene
MXPA06014888A (es) * 2004-06-15 2007-03-21 Medvet Science Pty Ltd Metodos para modular actividad celular que involucra esfingosina cinasa y agentes para los mismos, y variantes de esfingosina cinasa.
AU2005325227B2 (en) * 2004-10-28 2012-11-01 Lpath Therapeutics, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8324237B2 (en) * 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
WO2006135967A1 (en) * 2005-06-21 2006-12-28 Medvet Science Pty. Ltd. Modulation of egfr signalling by modulation of sphingosine kinase signalling
CA2612644A1 (en) * 2005-06-21 2006-12-28 Medvet Science Pty. Ltd. Modulation of sphingosine kinase signalling
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
DK2087002T3 (da) 2006-10-27 2014-10-27 Lpath Inc Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2019182191A1 (ko) 2018-03-21 2019-09-26 경북대학교 산학협력단 C0x2 아세틸화제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US5068175A (en) * 1989-05-26 1991-11-26 Board Of Regents, The University Of Texas Sysem Method of detecting ras oncogene related malignancies
JPH10182627A (ja) * 1996-12-20 1998-07-07 Sankyo Co Ltd 新規化合物Ｓ−１５１８３ａ及びＳ−１５１８３ｂ
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
EP1235913A2 (de) * 1998-05-26 2002-09-04 Sarah Spiegel Sphingosin-kinase, klonierung, expression und verfahren zur anwendung
EP1091745B1 (de) * 1998-06-29 2008-10-01 Children's Hospital Of Los Angeles Behandlung hyperproliferativer erkrankungen
ATE323153T1 (de) * 1999-05-13 2006-04-15 Johnson & Johnson Pharm Res Sphingosinekinase
WO2001031029A2 (en) * 1999-10-28 2001-05-03 Warner-Lambert Company Human sphingosine kinase gene
US6830916B2 (en) * 2000-03-02 2004-12-14 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
MXPA02009781A (es) * 2000-04-03 2004-09-06 Sankyo Co Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
CA2502257A1 (en) * 2002-10-14 2004-04-29 Jennifer Ruth Gamble A method of modulating endothelial cell activity by modulating the functional levels level of sphingosine kinase

Also Published As

Publication number Publication date
MXPA02011112A (es) 2004-08-19
CA2408196A1 (en) 2001-11-15
NO20025375L (no) 2003-01-07
EP1290182A4 (de) 2006-01-11
HK1054409A1 (zh) 2003-11-28
BR0110759A (pt) 2003-05-06
RU2326690C2 (ru) 2008-06-20
NZ543272A (en) 2009-04-30
EP1290182B1 (de) 2010-12-22
ZA200209066B (en) 2004-04-07
AUPQ744700A0 (en) 2000-06-01
AU2001256001B2 (en) 2007-03-15
DE60143697D1 (de) 2011-02-03
CN1436241A (zh) 2003-08-13
WO2001085953A1 (en) 2001-11-15
JP2003532423A (ja) 2003-11-05
NO20025375D0 (no) 2002-11-08
AU5600101A (en) 2001-11-20
US20040014635A1 (en) 2004-01-22
IL152672A0 (en) 2003-06-24
EP1290182A1 (de) 2003-03-12

Similar Documents

Publication Publication Date Title
DE60143697D1 (de) Sphingosinkinase und deren verwendungen
HUT74674A (en) Use of modafinil for preparing pharmaceutica compositions for the treatment of sleep apnoea and ventilation problems of central origin
MXPA05007151A (es) Polimeros terminados en maleimida hidroliticamente estables.
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
DE69811933D1 (de) Wirbelsäulenimplantat
DK1114105T3 (da) Udfældet calciumcarbonatprodukt med foröget glans og fremgangsmåde til at fremstille samme
DK1107974T3 (da) Nye hydratformer af alendronat natrium, processer til fremstilling deraf, og farmaceutiske sammensætninger deraf
EP1553225A4 (de) Velourskunstleder und seine herstellung
AU6769801A (en) Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
IL150060A0 (en) Novel purines
AP2003002785A0 (en) Treatment of t cell disorders
MXPA03010634A (es) Uso de inhibidores de proteasoma para tratar trastornos del ojo seco.
ATE417856T1 (de) Motilidverbindungen
TR200200278T2 (tr) Kalsilitik bileşimler
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
EP1328264A4 (de) Verwendung von estramustin-phosphat in der behandlung von knochenmetastasen
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
AU2002220712A1 (en) Stem cells, method for expansion in vitro and use thereof
DE69531627D1 (de) Humane hypertrophe chrondrozyten zelllinien
ATE454168T1 (de) Calcium-ergänzung zur senkung des risikos für prostatakrebs
WO2001025264A3 (en) Substituted phosphinate based peptide derivatives
UA32153A (uk) Спосіб формування трансплантату для зведення на промежину при черевно-анальних резекціях прямої кишки
UA42425A (uk) Спосіб лікування звичного вивиху плеча
UA36490A (uk) Спосіб лікування гнійно-септичних захворювань м'яких тканин

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties